Lisata Therapeutics

LSTA

Capitalización de mercado USD 11.1 M

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors.  Farrow fills a newly created seat, expanding the board from seven to eight members.

Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experimental drug certepetide for the treatment of pancreatic cancer and other solid tumors, the company said.  The US Patent and Trademark Office issued the Method of Use patent titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors.

LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002, a first-in-class antibody therapy for acromegaly, the company said on Monday.  Marea, which is developing medicines for cardioendocrine diseases, is advancing MAR002 as a potential new option for the rare endocrine disorder.

Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care

Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago.  MAR001 is an experimental antibody that blocks a protein called ANGPTL4, which helps fat tissue work properly, with the goal of lowering triglycerides and improving how the body handles fat.

SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from the Phase 2b TYDAL study of MAR001, a potential first-in-class monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), will be presented in a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) on Thursday announced it has acquired clinical-stage biotechnology company Marea Therapeutics, Inc. alongside an oversubscribed $225 million private placement financing.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases.  The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross proceeds.